HER2-positive breast cancer carries more HER2 protein on the tumor surface than normal cells. That protein acts like a stuck accelerator pedal, making the cancer spread faster than most hormone ...

Boehringer Ingelheim’s drug candidate for human epidermal growth factor receptor 2 (HER2)-mutated non-small cell lung cancer (NSCLC) has demonstrated a durable response of more than 14 months ...

Puma Biotechnology remains undervalued despite steady neratinib sales and a promising, though early-stage, pipeline. Learn ...

The UK drugs regulator has approved Seagen’s Tukysa as a third-line treatment for HER2-positive breast cancer, shortly after it was given a green light by the European Commission. Tukysa ...

New data could make HER2-directed antibody-drug conjugate (ADC) Enhertu an option for previously untreated breast cancer for the first time.

Drugs designed to target HER2-postive breast cancer could also benefit some patients with bile duct cancer, according to results of a patient trial to be presented on Thursday at the 36th EORTC ...

Novel Anti-HER2 Drugs 'Impressive' in Advanced Biliary Cancer — Response rates reached 41-47% with different approaches in rare disease by Ian Ingram , Managing Editor, MedPage Today June 3 ...

An investigational antibody-drug conjugate proved active and safe for patients with previously treated HER2-mutant non-small cell lung cancer (NSCLC), a phase II trial from China showed.

OS Therapies’ HER2-focused immunotherapy prevented patients’ lung cancer from returning in 33% of cases, hitting the primary goal of a phase 2 trial. The therapy, dubbed OST-HER2, uses a HER2 ...

What’s even more exciting is that this drug also works for people with lower levels of HER2 (called HER2-low cancers), which means it could help even more patients in the future.

However, targeted drugs that focus on the HER2 protein are often effective treatment options. If HER2-positive breast cancer is detected and treated early, the chance for a cure is possible. [1] ...

A bispecific antibody has entered the HER2 fray with a differentiated profile from traditional agents and a chance to challenge AstraZeneca and Daiichi Sankyo’s star antibody-drug conjugate Enhertu.